Bioceres Crop Solutions (NASDAQ:BIOX) Upgraded to Hold at Wall Street Zen

Key Points

• Bioceres Crop Solutions (NASDAQ:BIOX) was upgraded from a "sell" to a "hold" rating by analysts at Wall Street Zen, indicating a change in market sentiment towards the stock.
• Oppenheimer has lowered its price target for the stock from $7.00 to $6.00 while maintaining an "outperform" rating, resulting in an average price target of $8.38 for Bioceres.
• Institutional investors have significantly increased their positions in Bioceres, with one firm raising its stake by over 3,500% recently, highlighting growing institutional interest in the company.

Wall Street Zen upgraded shares of Bioceres Crop Solutions (NASDAQ:BIOX - Free Report) from a sell rating to a hold rating in a research report report published on Monday.

Separately, Oppenheimer reduced their price target on shares of Bioceres Crop Solutions from $7.00 to $6.00 and set an "outperform" rating for the company in a research report on Tuesday, July 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $8.38.

Bioceres Crop Solutions Stock Performance

NASDAQ BIOX traded down $0.18 on Monday, reaching $2.94. 142,189 shares of the company's stock traded hands, compared to its average volume of 201,095. The firm has a market cap of $184.62 million, a price-to-earnings ratio of -21.00, a P/E/G ratio of 1.36 and a beta of 0.44. The stock has a 50 day moving average price of $4.13 and a 200-day moving average price of $4.53. Bioceres Crop Solutions has a fifty-two week low of $2.87 and a fifty-two week high of $11.41. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.74 and a current ratio of 1.02.

Bioceres Crop Solutions (NASDAQ:BIOX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 21st. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.08. The business had revenue of $59.60 million during the quarter, compared to the consensus estimate of $61.80 million. Bioceres Crop Solutions had a negative net margin of 2.14% and a negative return on equity of 2.37%. Equities research analysts predict that Bioceres Crop Solutions will post -0.05 EPS for the current fiscal year.

Institutional Trading of Bioceres Crop Solutions

Several hedge funds have recently made changes to their positions in BIOX. JPMorgan Chase & Co. grew its stake in shares of Bioceres Crop Solutions by 17.0% in the 4th quarter. JPMorgan Chase & Co. now owns 105,301 shares of the company's stock valued at $640,000 after buying an additional 15,328 shares during the period. Jump Financial LLC acquired a new stake in shares of Bioceres Crop Solutions in the 4th quarter valued at $72,000. Stifel Financial Corp raised its holdings in shares of Bioceres Crop Solutions by 51.9% in the 4th quarter. Stifel Financial Corp now owns 61,958 shares of the company's stock valued at $377,000 after purchasing an additional 21,168 shares in the last quarter. Long Focus Capital Management LLC raised its holdings in shares of Bioceres Crop Solutions by 130.7% in the 4th quarter. Long Focus Capital Management LLC now owns 744,748 shares of the company's stock valued at $4,528,000 after purchasing an additional 421,931 shares in the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Bioceres Crop Solutions in the 4th quarter valued at $93,000. Hedge funds and other institutional investors own 17.68% of the company's stock.

Bioceres Crop Solutions Company Profile

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.